Biosimilars to Biobetters - the paths forward 2013

Whilst biopharmaceuticals remain a major component of the global therapeutics market, the ever expanding portfolio of products losing patent protection and with increasing healthcare costs remaining a poignant issue, the opportunity for development of competing, follow on biologics remains an attractive proposition for both Biotech and Pharma companies alike. However, as these biosimilar markets are captured how we manage the life cycle of these products and target specific patient and commercial benefits to maximise our product development strategies becomes increasingly important.

This Euroscicon biosimilars conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, biosimilar products to the market place.

Who should attend
Specialists in regulatory strategy and affairs, Biopharmaceutical developers/manufacturers including analytics/characterisation, marketing professionals, product enabling technology development companies